tetano
Editor, Senior Moderator
Front Immunol
. 2021 Dec 14;12:808527.
doi: 10.3389/fimmu.2021.808527. eCollection 2021.
Potentiating Lung Mucosal Immunity Through Intranasal Vaccination
Sean A Nelson[SUP] 1 [/SUP], Andrea J Sant[SUP] 1 [/SUP]
Affiliations
Abstract
Yearly administration of influenza vaccines is our best available tool for controlling influenza virus spread. However, both practical and immunological factors sometimes result in sub-optimal vaccine efficacy. The call for improved, or even universal, influenza vaccines within the field has led to development of pre-clinical and clinical vaccine candidates that aim to address limitations of current influenza vaccine approaches. Here, we consider the route of immunization as a critical factor in eliciting tissue resident memory (Trm) populations that are not a target of current licensed intramuscular vaccines. Intranasal vaccination has the potential to boost tissue resident B and T cell populations that reside within specific niches of the upper and lower respiratory tract. Within these niches, Trm cells are poised to respond rapidly to pathogen re-encounter by nature of their anatomic localization and their ability to rapidly deliver anti-pathogen effector functions. Unique features of mucosal immunity in the upper and lower respiratory tracts suggest that antigen localized to these regions is required for the elicitation of protective B and T cell immunity at these sites and will need to be considered as an important attribute of a rationally designed intranasal vaccine. Finally, we discuss outstanding questions and areas of future inquiry in the field of lung mucosal immunity.
Keywords: CD4 T cells; CD8 T cells; influenza; mucosal antibody response; tissue resident memory.
. 2021 Dec 14;12:808527.
doi: 10.3389/fimmu.2021.808527. eCollection 2021.
Potentiating Lung Mucosal Immunity Through Intranasal Vaccination
Sean A Nelson[SUP] 1 [/SUP], Andrea J Sant[SUP] 1 [/SUP]
Affiliations
- PMID: 34970279
- PMCID: PMC8712562
- DOI: 10.3389/fimmu.2021.808527
Abstract
Yearly administration of influenza vaccines is our best available tool for controlling influenza virus spread. However, both practical and immunological factors sometimes result in sub-optimal vaccine efficacy. The call for improved, or even universal, influenza vaccines within the field has led to development of pre-clinical and clinical vaccine candidates that aim to address limitations of current influenza vaccine approaches. Here, we consider the route of immunization as a critical factor in eliciting tissue resident memory (Trm) populations that are not a target of current licensed intramuscular vaccines. Intranasal vaccination has the potential to boost tissue resident B and T cell populations that reside within specific niches of the upper and lower respiratory tract. Within these niches, Trm cells are poised to respond rapidly to pathogen re-encounter by nature of their anatomic localization and their ability to rapidly deliver anti-pathogen effector functions. Unique features of mucosal immunity in the upper and lower respiratory tracts suggest that antigen localized to these regions is required for the elicitation of protective B and T cell immunity at these sites and will need to be considered as an important attribute of a rationally designed intranasal vaccine. Finally, we discuss outstanding questions and areas of future inquiry in the field of lung mucosal immunity.
Keywords: CD4 T cells; CD8 T cells; influenza; mucosal antibody response; tissue resident memory.